JPH09510466A - Use of dimethicone as transportation and carrier system and / or drug delivery system - Google Patents

Use of dimethicone as transportation and carrier system and / or drug delivery system

Info

Publication number
JPH09510466A
JPH09510466A JP7524363A JP52436395A JPH09510466A JP H09510466 A JPH09510466 A JP H09510466A JP 7524363 A JP7524363 A JP 7524363A JP 52436395 A JP52436395 A JP 52436395A JP H09510466 A JPH09510466 A JP H09510466A
Authority
JP
Japan
Prior art keywords
combination
pharmaceutical composition
dimethylpolysiloxane
dimethicone
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP7524363A
Other languages
Japanese (ja)
Inventor
シュミット，アルフレート
ウップマイヤー，ハンス−ユルゲン
Original Assignee
シュミット，アルフレート
ウップマイヤー，ハンス−ユルゲン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シュミット，アルフレート, ウップマイヤー，ハンス−ユルゲン filed Critical シュミット，アルフレート
Publication of JPH09510466A publication Critical patent/JPH09510466A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

(57)【要約】 本発明は、医薬品の運搬およびキャリアーシステムおよび／またはドラッグデリバリーシステムとして使用するジメチルポリシロキサン(ジメチコン)に関する。さらに本発明は、活性成分と組み合わせて運搬およびキャリアーシステムおよび／またはドラッグデリバリーシステムとしてジメチルポリシロキサンを含有する医薬組成物に関する。   (57) [Summary] The present invention relates to dimethylpolysiloxane (dimethicone) for use as a drug delivery and carrier system and / or drug delivery system. The invention further relates to pharmaceutical compositions containing dimethylpolysiloxane as a delivery and carrier system and / or drug delivery system in combination with an active ingredient.

Description

【発明の詳細な説明】 運搬およびキャリアーシステムおよび／またはドラッグデリバリー システムとしてのジメチコンの使用発明の技術分野 本発明は、医薬品の、例えば消化器系疾患の処置に用いる医薬品の運搬および キャリアーシステムおよび／またはドラッグデリバリーシステムとして用いるジ メチルポリシロキサン(ジメチコン)に関する。さらに本発明は、活性成分と組み 合わせて運搬およびキャリアーシステムおよび／またはドラッグデリバリーシス テムとしてジメチルポリシロキサンを含有する医薬組成物およびそれに関連する 方法に関する。 市販のジメチコン含有製剤は、腸の膨満、充満感(浮腫)および鼓腸などの症状 の処置に用いられている。さらに、食道、胃および十二指腸の炎症性および潰瘍 性疾患の処置にジメチコンの使用が記載されている。発明の背景 用量関連副作用を避けるために、医薬組成物製剤は、目的とする治療効果を発 揮するのに必要な活性成分の量のみが投与されるものでなければならない。 治療上の活性成分はその作用がまさに生じる部位で、あるいは局所および／ま たは全身の生物学的利用能が増大するように(例えば、肝での最初の通過作用を 防ぐことで)、あるいはできるだけ全身的な副作用を避けるように、吸収される 部位で利用されることが望ましい。 消化管の種々の部位で異なる性質があることにより、この事例では局所治療が 特に難しい。 継続的蠕動、長い消化管での化学的状態の多様性および消化管表面の形態が種 々の管の部位(例えば、食道、胃、十二指腸および結腸)における長い耐容性を保 つための障害となっている。 特に、慢性疾患、例えば消化管の炎症性、感染性、潰瘍性または癌性の変化の 場合には、長い時間で持続し得る直接的局所治療が望まれる。 さらに、局所的処置は、心血管系、肺、脳およびすべての空洞器官における障 害の場合にも望ましい。 局所処置は、適切な運搬およびキャリアーシステムおよび／またはドラッグデ リバリーシステムを必要とする。発明の要約 本発明は、活性成分が作用を生じまたは吸収される部位で、活性成分を持続的 に放出および／または固着せしめる、経口、経直腸および手術適用のための特殊 な医薬形態で使用されるキャリアーを提供する。 驚くべきことに、ジメチコンは、その独特の物理−化学的性質の故に、かかる 目的に理想的に適していることが見いだされた。ジメチコンは重合の程度によっ て非常に広範囲の粘度を有している。本発明において用いられるジメチコンの粘 度は、治療目的、処置する状態の本質および場所、および投与する薬剤によって 、変わってくる。望ましくは、１０−１００，０００mm2.５-1の範囲の動粘性率 を有するジメチコンが用いられる。 ３００−１５００mm2.５-1の範囲の動粘性率を有するジメチコンの使用が特に 望ましい。ジメチコンはまた、シリコンジオキシドで、例えばシメチコン製品に 含まれるように、補われ得る。 ジメチコンは、消化管の表面構造に特別の関連または親和性を示すことが分か った。ジメチコンの粘着性による粘着が増大し、消化管における活性成分の耐容 時間を、ジメチコンを運搬またはキャリアーシステムとして用いた場合、非常に 延長することができる。 しかし、消化管の化学的、形態的、生理的状態の相違のために消化管の上皮細 胞との親和性および関連は一定ではない。このように、消化管の特定の部分での 特定の薬剤について、運搬またはキャリアーシステムとしてのジメチコンの作用 を完全にするために、治療の本質、薬剤および消化管の部位によって適切な粘度 を有するジメチコンを選ばねばならない。これは容易に実験によって決められる 。 ジメチコンの使用は消化管の処置に限られる訳ではない。心循環系、肺、脳お よびすべての空洞器官の処置にも使用される。 本発明によって、ジメチコンは、細胞静止薬剤、免疫抑制剤、免疫調整および 免疫促進物質、生物反応修飾(ＢＲＭ)物質、放射−、化学−および光感作剤、コ ルチコイドなどの抗炎症物質、抗生物質、鎮痛剤、局所麻酔剤、抗炎症剤、非ス テロイド性抗リウマチ剤、抗ウイルス物質、ビスマス製剤、および能動性抑制お よび能動性向上物質について運搬およびキャリアーシステムまたはドラッグデリ バリーシステムとして特に適切であることが見いだされた。 光感作剤δ−アミノレブリン酸(ＡＬＡ)、Ｈ2アンタゴニスト(ラニチジンおよ びシメチジンなど)およびプロトンポンプ阻害剤(オメプラゾールおよびランソプ ラゾールなど)についてキャリアーとしてのジメチコンの機能が特に望ましい。 上記した物質の一つと共にジメチコンを含む医薬組成物が消化管の炎症性、感 染性、潰瘍性および癌性疾患の処置において特に適切である。 消化管の下位部における障害の処置では、ジメチコンを含む医薬組成物は、消 化管の上位部にジメチコンおよび活性成分が残留するのを防ぐために通常の方法 に従って経腸型に処方される。一方、医薬組成物の性質を、消化管の下位部への 親和性を増大するように調整しなければならない。 直接的な利用、例えば内視鏡、気管支鏡、直腸鏡の生検的チャンネル、内手術 または注入を経る利用は、特に望ましい。 ジメチコン含有医薬組成物は、高度分散シリコンジオキシドおよび／または製 薬上許容される界面活性剤をも含み得る。 ジメチルポリシロキサンの界面活性剤に対する比率は、望ましくは３−１０： １であり、特に４−６：１であり、そして高度分散シリコンジオキシドのジメチ ルポリシリコンに対する比率は、望ましくは３−５０％(wt/wt)である。後者の 比率のより望ましい範囲は３０−４０％(wt/wt)であり、３５−３６％の値が特 に望ましい。 界面活性剤の濃度は望ましくは少なくとも１.５％(wt/wt)である。特に望まし いジメチコン処方は界面活性剤を８−１０％含む。 ステアリン酸塩または長鎖のアルカン酸、特にＣ11−Ｃ18のアルカン酸、例え ばミリスチン酸、パルミチン酸およびステアリン酸など、およびその塩、例えば マグネシウムまたはカルシウム塩など、およびその混合物が製薬上許容される界 面活性剤として適切に使用できる。 本発明を次の実施例で明示する。 実施例 δ−アミノレブリン酸(ＡＬＡ)を含むエマルジョン 量／用量 mg／250ml ＡＬＡ 5,000.0000 シメチコン 2,000.0000 (ジメチコン1000−ＳｉＯ2９４：６) アエロジル２００ 125.0000 コリドンＣＬＭ1 2,500.0000 ヒドロキシエチルセルロース 20,000.0000 ヴィーガムＫ2 2,500.0000 シナモン油ＤＡ Ｂ１０ 0.1228 ８５％インジゴチン 0.0250 蒸留水 適量 250ml １＝ポリビニルピロリドン(ＩＮＮ：プロビドン) ２＝コロイド性マグネシウム＝アルミニウムシリケート 実施例のエマルジョンは、消化管腫瘍の光力学的治療を意図するものであり、 効果が発揮されるべきその部位に、内視鏡の手段で使用される。 本発明の具体的な例を記載したが、この具体例を、本発明の方法を利用する他 の具体例の提供のために変え得ることは明らかである。従って、本発明の範囲は 実施例として提示された特別の具体例によるのではなく、別記の請求項により定 められるものである。Description: Use of dimethicone as a delivery and carrier system and / or drug delivery system TECHNICAL FIELD OF THE INVENTION The present invention relates to the delivery and carrier system of pharmaceuticals, for example for the treatment of digestive disorders and / or Alternatively, it relates to dimethylpolysiloxane (dimethicone) used as a drug delivery system. The present invention further relates to pharmaceutical compositions containing dimethylpolysiloxane as delivery and carrier systems and / or drug delivery systems in combination with active ingredients and related methods. Commercially available dimethicone-containing formulations are used for the treatment of conditions such as intestinal bloating, fullness (edema) and flatulence. Furthermore, the use of dimethicone has been described for the treatment of inflammatory and ulcerative diseases of the esophagus, stomach and duodenum. BACKGROUND OF THE INVENTION In order to avoid dose-related side effects, pharmaceutical composition formulations should be administered in an amount only of the active ingredient necessary to exert the desired therapeutic effect. The therapeutically active ingredient is at the site where its action occurs, or in such a way that local and / or systemic bioavailability is increased (eg, by preventing its first transit action in the liver), or as systemically as possible. It is desirable to use it at the site of absorption so as to avoid adverse side effects. Local treatment is particularly difficult in this case due to the different nature of different parts of the digestive tract. Persistent peristalsis, variability in chemical status in the long digestive tract and morphology of the digestive tract surface impede long-term tolerability at various vascular sites (e.g., esophagus, stomach, duodenum and colon). There is. In particular, in the case of chronic diseases such as inflammatory, infectious, ulcerative or cancerous changes of the digestive tract, a direct topical treatment that can last for a long time is desired. Furthermore, local treatment is also desirable in the case of disorders in the cardiovascular system, lungs, brain and all hollow organs. Topical treatment requires a suitable delivery and carrier system and / or drug delivery system. SUMMARY OF THE INVENTION The present invention is used in a special pharmaceutical form for oral, rectal and surgical applications, which results in a sustained release and / or sticking of the active ingredient at the site where it takes effect or is absorbed. To provide a successful career. Surprisingly, dimethicone has been found to be ideally suited for such purposes because of its unique physico-chemical properties. Dimethicone has a very wide range of viscosities depending on the degree of polymerization. The viscosity of dimethicone used in the present invention will depend on the therapeutic purpose, the nature and location of the condition being treated, and the drug being administered. Desirably, dimethicone having a kinematic viscosity in the range of 10-100,000 mm 2.5 -1 is used. The use of dimethicone having a kinematic viscosity in the range of 300-1500 mm 2.5 -1 is particularly desirable. Dimethicone can also be supplemented with silicon dioxide, such as is included in simethicone products. Dimethicone was found to have a particular association or affinity with the surface structure of the digestive tract. The stickiness due to the stickiness of dimethicone can be increased and the tolerability time of the active ingredient in the digestive tract can be greatly extended when dimethicone is used as a transport or carrier system. However, due to differences in the chemical, morphological and physiological state of the digestive tract, the affinity and association with the epithelial cells of the digestive tract are not constant. Thus, for a particular drug in a particular part of the gastrointestinal tract, in order to complete the action of dimethicone as a delivery or carrier system, dimethicone having an appropriate viscosity depending on the nature of the treatment, the drug and the site of the gastrointestinal tract. Must be selected. This is easily determined by experiment. The use of dimethicone is not limited to treating the digestive tract. It is also used in the treatment of the cardiovascular system, lungs, brain and all hollow organs. According to the invention, dimethicone is a cytostatic agent, an immunosuppressive agent, an immunomodulatory and immunostimulatory agent, a biological response modifier (BRM) agent, a radiation-, chemo- and photosensitizer, an anti-inflammatory agent such as a corticoid, an antibiotic. , Analgesics, local anesthetics, anti-inflammatory agents, non-steroidal anti-rheumatic agents, antiviral agents, bismuth preparations, and active depressant and enhancers have been found to be particularly suitable as delivery and carrier or drug delivery systems It was The function of dimethicone as a carrier for the photosensitizer δ-aminolevulinic acid (ALA), H 2 antagonists (such as ranitidine and cimetidine) and proton pump inhibitors (such as omeprazole and lansoprazole) is particularly desirable. Pharmaceutical compositions comprising dimethicone together with one of the substances mentioned above are particularly suitable in the treatment of inflammatory, infectious, ulcerative and cancerous diseases of the digestive tract. For the treatment of disorders in the lower part of the digestive tract, pharmaceutical compositions containing dimethicone are formulated enterally according to the usual methods to prevent residual dimethicone and active ingredients in the upper part of the digestive tract. On the other hand, the properties of the pharmaceutical composition must be adjusted to increase its affinity for the lower part of the digestive tract. Direct use, such as endoscopic, bronchoscopic, rectal biopsy channel, via internal surgery or infusion, is particularly desirable. The dimethicone-containing pharmaceutical composition may also include a highly dispersed silicon dioxide and / or a pharmaceutically acceptable surfactant. The ratio of dimethylpolysiloxane to surfactant is preferably 3-10: 1, especially 4-6: 1, and the ratio of highly dispersed silicon dioxide to dimethylpolysilicon is preferably 3-50%. (wt / wt). A more desirable range for the latter ratio is 30-40% (wt / wt), with values of 35-36% being particularly desirable. The concentration of surfactant is desirably at least 1.5% (wt / wt). A particularly desirable dimethicone formulation contains 8-10% surfactant. Stearates or long-chain alkanoic acids, especially C 11 -C 18 alkanoic acids, such as myristic acid, palmitic acid and stearic acid, and salts thereof, such as magnesium or calcium salts, and mixtures thereof are pharmaceutically acceptable. Can be suitably used as a surfactant. The invention is demonstrated in the following examples. Example Emulsion containing δ-aminolevulinic acid (ALA) Amount / dose mg / 250 ml ALA 5,000.0000 Simethicone 2,000.0000 (Dimethicone 1000-SiO 2 94: 6) Aerosil 200 125.0000 Kollidon CLM 1 2,500.0000 Hydroxyethylcellulose 20,000.0000 Vegum K 2 2,500.0000 Cinnamon oil DA 10 0.1228 85% Indigotine 0.0250 Distilled water Appropriate amount 250 ml 1 = Polyvinylpyrrolidone (INN: Providone) 2 = Colloidal magnesium = Aluminum silicate The emulsions of the examples are intended for the photodynamic treatment of gastrointestinal tumors, and exert their effects. Used by endoscopic means to the site to be done. Although a specific example of the present invention has been described, it will be apparent that this example may be varied to provide other embodiments utilizing the methods of the present invention. The scope of the invention is, therefore, defined by the appended claims rather than by the specific embodiments presented as examples.

───────────────────────────────────────────────────── フロントページの続き (81)指定国 ＥＰ(ＡＴ，ＢＥ，ＣＨ，ＤＥ， ＤＫ，ＥＳ，ＦＲ，ＧＢ，ＧＲ，ＩＥ，ＩＴ，ＬＵ，Ｍ Ｃ，ＮＬ，ＰＴ，ＳＥ)，ＯＡ(ＢＦ，ＢＪ，ＣＦ，ＣＧ ，ＣＩ，ＣＭ，ＧＡ，ＧＮ，ＭＬ，ＭＲ，ＮＥ，ＳＮ， ＴＤ，ＴＧ)，ＡＰ(ＫＥ，ＭＷ，ＳＤ，ＳＺ，ＵＧ)， ＡＭ，ＡＴ，ＡＵ，ＢＢ，ＢＧ，ＢＲ，ＢＹ，ＣＡ，Ｃ Ｈ，ＣＮ，ＣＺ，ＤＥ，ＤＫ，ＥＳ，ＦＩ，ＧＢ，ＧＥ ，ＨＵ，ＪＰ，ＫＥ，ＫＧ，ＫＰ，ＫＲ，ＫＺ，ＬＫ， ＬＴ，ＬＵ，ＬＶ，ＭＤ，ＭＧ，ＭＮ，ＭＷ，ＮＬ，Ｎ Ｏ，ＮＺ，ＰＬ，ＰＴ，ＲＯ，ＲＵ，ＳＤ，ＳＥ，ＳＩ ，ＳＫ，ＴＪ，ＴＴ，ＵＡ，ＵＳ，ＵＺ，ＶＮ────────────────────────────────────────────────── ─── Continuation of front page    (81) Designated countries EP (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, M C, NL, PT, SE), OA (BF, BJ, CF, CG , CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), AP (KE, MW, SD, SZ, UG), AM, AT, AU, BB, BG, BR, BY, CA, C H, CN, CZ, DE, DK, ES, FI, GB, GE , HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, N O, NZ, PL, PT, RO, RU, SD, SE, SI , SK, TJ, TT, UA, US, UZ, VN

Claims (1)

【特許請求の範囲】 １．医薬組成物の製剤のための活性成分の運搬またはキャリアーシステムとし てのジメチルポリシロキサンの使用。 ２．光感作剤と組み合わせてジメチルポリシロキサンを含有する医薬組成物。 ３．光感作剤がδ−アミノレブリン酸ＡＬＡである請求項２記載の医薬組成物 。 ４．Ｈ2−アンタゴニストおよび／またはプロトンポンプ阻害剤と組み合わせ てジメチルポリシロキサンを含有する医薬組成物。 ５．１またはそれ以上の抗生物質と組み合わせてジメチルポリシロキサンを含 有する医薬組成物。 ６．免疫調整物質または免疫促進物質と組み合わせてジメチルポリシロキサン を含有する医薬組成物。 ７．鎮痛剤または局所麻酔剤と組み合わせてジメチルポリシロキサンを含有す る医薬組成物。 ８．抗炎症剤または非ステロイド性抗リウマチ剤と組み合わせてジメチルポリ シロキサンを含有する医薬組成物。 ９．抗ウイルス物質と組み合わせてジメチルポリシロキサンを含有する医薬組 成物。 １０．活性成分がコルチコイドである請求項１の使用。 １１．ビスマス製剤と組み合わせてジメチルポリシロキサンを含有する医薬組 成物。 １２．能動性−阻害または能動性−向上物質と組み合わせてジメチルポリシロ キサンを含有する医薬組成物。 １３．ＢＲＭ(生物反応修飾)物質と組み合わせてジメチルポリシロキサンを含 有する医薬組成物。[Claims] 1. Use of dimethylpolysiloxane as a carrier or carrier system for the active ingredients for the formulation of pharmaceutical compositions. 2. A pharmaceutical composition containing dimethylpolysiloxane in combination with a photosensitizer. 3. The pharmaceutical composition according to claim 2, wherein the photosensitizer is δ-aminolevulinic acid ALA. 4. H 2 - antagonists and / or pharmaceutical compositions containing dimethylpolysiloxane in combination with a proton pump inhibitor. 5. A pharmaceutical composition containing dimethylpolysiloxane in combination with one or more antibiotics. 6. A pharmaceutical composition comprising dimethylpolysiloxane in combination with an immunomodulator or immunostimulator. 7. A pharmaceutical composition containing dimethylpolysiloxane in combination with an analgesic or a local anesthetic. 8. A pharmaceutical composition containing dimethylpolysiloxane in combination with an anti-inflammatory or non-steroidal anti-rheumatic agent. 9. A pharmaceutical composition containing dimethylpolysiloxane in combination with an antiviral substance. 10. Use according to claim 1, wherein the active ingredient is a corticoid. 11. A pharmaceutical composition containing dimethylpolysiloxane in combination with a bismuth formulation. 12. A pharmaceutical composition comprising dimethylpolysiloxane in combination with an activity-inhibiting or activity-enhancing substance. 13. A pharmaceutical composition containing dimethylpolysiloxane in combination with a BRM (biological response modifier) substance.
JP7524363A 1994-03-18 1995-03-15 Use of dimethicone as transportation and carrier system and / or drug delivery system Withdrawn JPH09510466A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4409357.8 1994-03-18
DE4409357A DE4409357C2 (en) 1994-03-18 1994-03-18 Use of Dimeticon to eradicate Heliobacter pylori
PCT/EP1995/000973 WO1995025545A1 (en) 1994-03-18 1995-03-15 The use of dimeticone as a transport and carrier system and/or drug delivery system

Publications (1)

Publication Number Publication Date
JPH09510466A true JPH09510466A (en) 1997-10-21

Family

ID=6513210

Family Applications (1)

Application Number Title Priority Date Filing Date
JP7524363A Withdrawn JPH09510466A (en) 1994-03-18 1995-03-15 Use of dimethicone as transportation and carrier system and / or drug delivery system

Country Status (14)

Country Link
EP (1) EP0804242A1 (en)
JP (1) JPH09510466A (en)
CN (1) CN1244129A (en)
AU (1) AU699199B2 (en)
CA (1) CA2185882A1 (en)
CZ (1) CZ300796A3 (en)
DE (1) DE4409357C2 (en)
FI (1) FI963682A (en)
HU (1) HU215595B (en)
NO (1) NO963893L (en)
NZ (1) NZ282805A (en)
PL (1) PL316307A1 (en)
SK (1) SK132496A3 (en)
WO (1) WO1995025545A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100245A (en) * 1999-09-07 2000-08-08 Mcneil-Ppc, Inc. Use of simethicone to treat ulcerative colitis
BR0318319A (en) * 2003-05-25 2006-07-18 Yuwan Wang preparation methods and formulations / compositions sustained by the use of dimethicone as a vehicle

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3848M (en) * 1964-05-04 1966-01-17 Robert Schapiro Therapeutic associations for the treatment of numerous organic or functional digestive disorders.
GB1357737A (en) * 1970-10-09 1974-06-26 Arpic Sa Sustained release pharmaceutical compositions
NZ217844A (en) * 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4837029A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Low foaming, aqueously homogenizable rifampin composition
US5446070A (en) * 1991-02-27 1995-08-29 Nover Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
WO1990007930A1 (en) * 1989-01-19 1990-07-26 Steigerwald Arzneimittelwerk Gmbh Use of dimethylpolysiloxane for treating disorders of the gastrointestinal tract
IE903302A1 (en) * 1989-09-15 1991-04-10 Pehrom Pharmaceutical Corp Topical preparation for treatment of aphthous ulcers and¹other lesions
NZ235876A (en) * 1989-11-01 1992-06-25 Mcneil Ppc Inc Pharmaceutical compositions containing effective amount of antidiarrheal composition and antiflatulent effective amount of simethicone
US5229137A (en) * 1992-05-06 1993-07-20 Brigham And Women's Hospital, Inc. Methods and pharmaceutical compositions for treating episodic heartburn
WO1994003209A1 (en) * 1992-07-29 1994-02-17 Merck & Co., Inc. Dexibuprofen/antacid/simethicone combinations

Also Published As

Publication number Publication date
PL316307A1 (en) 1997-01-06
HUT75711A (en) 1997-05-28
NZ282805A (en) 1998-02-26
CN1244129A (en) 2000-02-09
EP0804242A1 (en) 1997-11-05
NO963893D0 (en) 1996-09-17
AU2071395A (en) 1995-10-09
SK132496A3 (en) 1997-06-04
NO963893L (en) 1996-11-04
HU9602839D0 (en) 1996-12-30
CZ300796A3 (en) 1997-09-17
DE4409357C2 (en) 1996-10-17
HU215595B (en) 1999-01-28
FI963682A0 (en) 1996-09-17
CA2185882A1 (en) 1995-09-28
DE4409357A1 (en) 1995-09-21
WO1995025545A1 (en) 1995-09-28
AU699199B2 (en) 1998-11-26
FI963682A (en) 1996-11-13

Similar Documents

Publication Publication Date Title
ES2254523T3 (en) TREATMENT OF MUCOSITIS.
US20230241220A1 (en) Material and method for treating internal cavities
AU753206B2 (en) Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
JPH05194215A (en) Therapeutic composition for narial administration containing 5-benzoyl-2,3-dihydro-1h-pyrrolidine- 1-carboxylic acid
JPS6261917A (en) Percutaneously absorbable aqueous medicine of arylpropionic acid derivative and manufacture
WO2002096406A1 (en) Medicinal compositions
EP2139451B1 (en) Topical compositions containing magaldrate
WO2013011504A1 (en) Materials and method for treating internal body cavities
PT1392254E (en) Micellar drug delivery systems for hydrophobic drugs
Bharat et al. A review: Novel advances in semisolid dosage forms & patented technology in semisolid dosage forms
KR20040089628A (en) Liquid matrix undergoing phase transfer in vivo and liquid oral preparations
RU2542449C2 (en) Compositions and methods of treating bladder cancer
JP2001199883A (en) External preparation for antiinflammatory analgesic purpose
US5834004A (en) Enteral composition comprising dimethicone and a photosensitizer and a method of delivery
JPH09510466A (en) Use of dimethicone as transportation and carrier system and / or drug delivery system
US20050112213A1 (en) Compositions of improved sucralfate and sucrose octasulfate and method of use
JP4066466B2 (en) Ointment containing sugar alcohols
US20220202773A1 (en) Material and method for treating cancer
RU2711090C2 (en) Non-staining gel composition containing nimesulide, for topical application
JP2006052172A (en) Pyrazolone-based pharmaceutical preparation
JP2003516957A (en) Particularly, a gel composition for containing an active ingredient in a solution or suspension for application to a mucous membrane and a production method
WO2009007827A2 (en) Novel diclofenac esters and uses thereof
EP2563351A1 (en) Adhesive slow-release formulations for the local administration of curcumin
JPH05117141A (en) Antiinflammatory analgesic gel preparation containing adrenal essence
AU2022399569A1 (en) Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040330

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040629

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20051011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090512

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090715

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090817

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100621